Business Context and Reporting Period
This Form 8-K, dated October 21, 2022, is filed by Health Sciences Acquisitions Corporation 2 (HSAC2), a Cayman Islands exempted company and emerging growth company. The filing reports on amendments to definitive agreements regarding a proposed business combination with Orchestra BioMed, Inc. (Orchestra). The transaction involves a two-step process: the domestication of HSAC2 from the Cayman Islands to Delaware, followed by a merger where a subsidiary of HSAC2 merges with Orchestra.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for the reporting period, as this is a current report regarding a transactional agreement rather than a periodic financial statement.
- Minimum Available Cash Condition: The Backstop Agreement targets a minimum of $60 million in Parent Closing Cash.
- Forward Purchase Commitment: RTW Funds committed to purchasing $10 million of HSAC2 ordinary shares.
- Share Purchase Price: Originally set at $10.00 per share under the Backstop and Forward Purchase Agreements.
Material Changes Versus Prior Period
On October 21, 2022, the parties amended the Backstop Agreement and Forward Purchase Agreement previously executed on July 4, 2022. The material changes include:
- Price Cap Adjustment: The per-share purchase price under both agreements is now capped at the redemption price available to HSAC2 shareholders at the shareholder meeting approving the Business Combination, rather than a fixed $10.00.
- Voting Restrictions: Shares purchased under these agreements, or acquired by RTW Funds outside the redemption offer, will not be voted in favor of the Business Combination.
- Redemption Waiver: RTW Funds agreed to waive redemption rights regarding these specific purchases during the vote to approve the Business Combination.
Guidance, Outlook, and Risks
The filing outlines the structural mechanics of the merger and the financial backstop designed to ensure sufficient liquidity at closing. No forward-looking financial guidance or management commentary on future operational performance is provided in this document.
Key Contingencies and Risks:
- The transaction is contingent upon shareholder approval and the satisfaction of the Minimum Available Cash Condition.
- The amended agreements introduce uncertainty regarding the final purchase price, as it is tied to the redemption price determined at the shareholder meeting.
- The voting restrictions on shares held by RTW Funds may impact the dynamics of shareholder approval.
Investor Verification Checklist
- Verify the final redemption price per share at the shareholder meeting to determine the actual cost basis for the Backstop and Forward Purchase shares.
- Confirm the total amount of cash in the trust and the extent of shareholder redemptions to assess if the $60 million Minimum Available Cash Condition is met.
- Review the voting results of the shareholder meeting to ensure the Business Combination is approved despite the voting restrictions on RTW Funds' shares.
- Monitor the status of the domestication process from the Cayman Islands to Delaware as a prerequisite to the merger closing.